Ticarcillin + Clavulanic AcidThird Party Manufacturing in India

Ticarcillin + Clavulanic Acid is a combination antibiotic that works through two complementary mechanisms. Ticarcillin is a carboxypenicillin beta-lactam antibiotic that kills bacteria by preventing the cross-linking of peptidoglycan during bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs) inside the bacterial cell wall, inhibiting the final transpeptidation step required for cell wall integrity, which ultimately causes bacterial cell lysis and death. Clavulanic acid is a beta-lactamase inhibitor that protects ticarcillin from enzymatic degradation. Many resistant bacteria produce beta-lactamase enzymes that cleave the beta-lactam ring of penicillins, rendering them inactive. Clavulanic acid acts as a suicide substrate, irreversibly binding to these beta-lactamases and neutralizing them. This allows ticarcillin to reach its target intact and exert its bactericidal effect against otherwise resistant organisms. The combination restores ticarcillin's activity against beta-lactamase-producing strains of bacteria including Pseudomonas aeruginosa, making it an important option for hospital-acquired and severe infections.

Therapeutic Uses

Ticarcillin + Clavulanic Acid is prescribed for the treatment of serious bacterial infections caused by susceptible beta-lactamase-producing organisms:

• Septicaemia and Bacteraemia: For bloodstream infections caused by Klebsiella spp., Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa
• Lower Respiratory Tract Infections: Including hospital-acquired pneumonia caused by S. aureus, Haemophilus influenzae, and Klebsiella spp.
• Complicated Urinary Tract Infections: For pyelonephritis and other complicated UTIs caused by E. coli, Pseudomonas aeruginosa, and other Enterobacteriaceae
• Intra-abdominal Infections: Including peritonitis caused by E. coli, Klebsiella pneumoniae, and Bacteroides fragilis group
• Bone and Joint Infections: Caused by susceptible S. aureus isolates
• Skin and Skin Structure Infections: Severe soft tissue infections
• Febrile Neutropenia: Used in combination with aminoglycosides in immunocompromised patients

Why Manufacturers Choose Ticarcillin + Clavulanic Acid

Ticarcillin + Clavulanic Acid remains a critical injectable antibiotic in hospital formularies, particularly for empiric coverage of Gram-negative infections including Pseudomonas. The combination offers a proven safety profile and broad-spectrum activity that makes it a workhorse in intensive care and surgical units. Indian pharmaceutical manufacturers maintain consistent production of this combination, with demand from hospital supply contracts and government tender business in both domestic and regulated markets. The WHO-GMP certified manufacturing infrastructure required for sterile injectables makes this a high-value product for third party manufacturing and institutional supply.